RELAPSED NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough blood cancers: experimental drug enters human testing
Disease control OngoingThis early-stage trial tests a new drug called BGB-21447 in about 112 people whose B-cell blood cancers (like lymphoma or leukemia) have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
New drug combo aims to tackle tough lymphoma
Disease control OngoingThis early-stage trial tests the safety and correct dose of combining two cancer drugs, loncastuximab tesirine and venetoclax, for people with non-Hodgkin lymphoma that has come back or not responded to treatment. About 23 adults will take part. The goal is to find a safe dose an…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
Can a zap of radiation boost CAR T-Cell success in tough lymphomas?
Disease control OngoingThis early-phase study looks at whether giving low-dose radiation before CAR T-cell therapy is practical and safe for people with B-cell lymphoma that has come back or not responded to treatment. About 33 adults will receive radiation to bridge them to a CAR T-cell infusion. The …
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Nebraska • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
15-Year safety check for caribou cell therapy patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows about 150 people who have already received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to track any long-term side effects for up to 15 years after treatment. No new treatments are given—just regular check-ups to monitor safety…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Sponsor: Caribou Biosciences, Inc. • Aim: Knowledge-focused
Last updated May 13, 2026 16:01 UTC